semaglutide elisa detection limit versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial Spotlight on the Mechanism of

Readers should understand that compounded GLP-1 availability may depend on current federal policy, state rules, individual pharmacy requirements, current shortage status, and clinician judgment

et al.: Triple-Hormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial

Uncertainty was assessed through sensitivity analyses, including a scenario analysis using clinical data from the STEP 2 trial and a previously published and validated Core Diabetes Model to investigate a cohort with type 2 diabetes at baseline

Removal of the N-terminal 55 residues or ECD deletion completely abolished the activation effect of compound 2 despite that it binds to the cytoplasmic side of TM6, consistent with our previous report that ECD is required for GLP-1R and GCGR activation 34